EBM Technologies (8409) reported revenue of NT$29.5 million for Oct 2026, +184.8% year on year and -6.0% from the previous month. Revenue for Jan–Oct 2026 was NT$184.3 million (+2.0% year on year).
In Oct 2026, it ranked No. 120 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$29.5 million | +184.8% | -6.0% |
| Sep 2026 | NT$31.4 million | -60.3% | +50.0% |
| Aug 2026 | NT$21 million | +39.2% | +39.5% |
| Jul 2026 | NT$15 million | -22.7% | +10.2% |
| Jun 2026 | NT$13.6 million | +20.9% | +0.0% |
| May 2026 | NT$13.6 million | +16.5% | +61.1% |
| Apr 2026 | NT$8.5 million | -19.3% | -47.7% |
| Mar 2026 | NT$16.2 million | +54.6% | -3.6% |
| Feb 2026 | NT$16.8 million | +105.6% | -10.5% |
| Jan 2026 | NT$18.7 million | +300.6% | -69.3% |
| Dec 2025 | NT$61.1 million | -28.8% | +440.7% |
| Nov 2025 | NT$11.3 million | -16.8% | +8.9% |
| Oct 2025 | NT$10.4 million | -86.8% | -86.9% |
| Sep 2025 | NT$79.1 million | +580.3% | +425.3% |
| Aug 2025 | NT$15.1 million | +35.0% | -22.5% |
| Jul 2025 | NT$19.4 million | -23.5% | +72.5% |
| Jun 2025 | NT$11.3 million | +3.3% | -3.6% |
| May 2025 | NT$11.7 million | +22.5% | +11.5% |
| Apr 2025 | NT$10.5 million | +43.0% | +0.3% |
| Mar 2025 | NT$10.5 million | -1.8% | +28.3% |
| Feb 2025 | NT$8.2 million | +8.4% | +74.4% |
| Jan 2025 | NT$4.7 million | -46.5% | -94.6% |
| Dec 2024 | NT$85.8 million | +28.4% | +531.6% |
| Nov 2024 | NT$13.6 million | -28.5% | -82.8% |
| Oct 2024 | NT$78.7 million | +579.5% | +576.7% |
Jan–Oct 2026 cumulative: NT$184.3 million (+2.0% YoY)
Other Biotech & Medical companies
Compare with peers: EBM Technologies vs PEC / EBM Technologies vs Lotus Pharm / EBM Technologies vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月驗收結案之專案較上月增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16